DYRK2 and lung carcinoma: Hence, using a similar strategy as suggested previously to generate conditional DYRK2 depletion in genetically engineered lung cancer mouse models for NSCLC, squamous-cell lung cancer, and other subtypes (108) could provide more clarity to this debate.